|
Essential Tremor
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that alterations at the CYP2C gene locus are associated with the risk for ET.
|
17627038 |
2007 |
|
Xerocytosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Non-genetic factor, omeprazole co-medication, was strongly associated with PHT-induced DRESS/DHS in addition to variants in HLA-B and CYP2C genes.
|
28391407 |
2017 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CYP2C and IL-6 expression in breast cancer.
|
14759713 |
2004 |
|
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The level of CYP2C gene expression in samples of lung cancer was significantly higher than in normal lung tissue, but the level of CYP3A4 gene expression was not.
|
11488523 |
2001 |
|
Drug Resistant Epilepsy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We aimed to evaluate the association of non-response to antiepileptic pharmacotherapy with the frequency of variant alleles in the drug transporter genes ABCB1 and ABCC2 or in the CYP2C locus in young patients with epilepsy and an independent cohort of adults with drug-refractory epilepsy.
|
19415824 |
2009 |
|
Primary malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The level of CYP2C gene expression in samples of lung cancer was significantly higher than in normal lung tissue, but the level of CYP3A4 gene expression was not.
|
11488523 |
2001 |
|
DEAFNESS-HYPOGONADISM SYNDROME
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Non-genetic factor, omeprazole co-medication, was strongly associated with PHT-induced DRESS/DHS in addition to variants in HLA-B and CYP2C genes.
|
28391407 |
2017 |
|
Coronary Artery Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of CYP2C or CYP2J2 have a pathologic impact on coronary artery diseases.
|
21476972 |
2011 |
|
Drug Hypersensitivity Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Non-genetic factor, omeprazole co-medication, was strongly associated with PHT-induced DRESS/DHS in addition to variants in HLA-B and CYP2C genes.
|
28391407 |
2017 |
|
Carcinogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
To estimate the role of cytochrome P450 in carcinogenesis of the colon, expression patterns and protein levels of four representative CYPs (CYP2C, CYP2E1, CYP3A4 and CYP3A5) were determined in colon mucosa of normal and adenomatous colonic tissue of patients with adenomas and disease-free controls.
|
16281975 |
2005 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.
|
21716162 |
2011 |
|
Hypertensive disease
|
0.040 |
Biomarker
|
group |
BEFREE |
Studies with rat genetic models of hypertension pointed to roles for the CYP2C and CYP4A arachidonic acid epoxygenases and ω-hydroxylases in tubular transport, hemodynamics, and blood pressure control.
|
25986599 |
2015 |
|
Hypertensive disease
|
0.040 |
Biomarker
|
group |
BEFREE |
The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population.
|
28513222 |
2017 |
|
Hypertensive disease
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Overall, nifedipine and verapamil blunts CSA hypertension but variably affected concomitantly enhanced EDHF-dependent renal vasodilations and alterations in CYP2C/CYP4A signaling.
|
28899749 |
2017 |
|
Hypertensive disease
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Associations between genetically controlled alterations in blood pressure and the activity and/or transcriptional regulation of the kidney Cyp2c AA epoxygenases and Cyp4a omega-hydroxylases revealed a role for these enzymes in the pathophysiology of hypertension, a leading cause of cardiovascular, cerebral, and renal morbidity and mortality.
|
17597703 |
2007 |
|
Metabolic Diseases
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Furthermore, ATR induced CYP-related enzymes metabolism disorders by activating the nuclear xenobiotic receptors response (NXRs including AHR, CAR, and PXR) and increased expression of several CYP isoforms (including CYP1B1 and CYP2C18) and thereby producing mitochondrial dysfunction.
|
29865786 |
2018 |
|
Metabolic Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
CYP2C enzymes are responsible for the oxidative metabolism of a diverse number of drugs for the treatment of type 2 diabetes mellitus, a severe metabolic disorder with high prevalence.
|
21939641 |
2011 |
|
Retinal Diseases
|
0.020 |
AlteredExpression
|
group |
BEFREE |
We found that CYP2C (localized in wild-type monocytes/macrophages) is upregulated in oxygen-induced retinopathy, whereas sEH is suppressed, resulting in an increased retinal epoxide:diol ratio.
|
24458713 |
2014 |
|
Retinal Diseases
|
0.020 |
PosttranslationalModification
|
group |
BEFREE |
Soluble epoxide hydrolase inhibition, which blocks breakdown and inactivation of CYP2C ω-3 LCPUFA-derived active metabolites, increased oxygen-induced retinopathy and CNV in vivo.
|
27417579 |
2016 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
CYP2B6 plus P450 reductase and CYP2C18-Met plus P450 reductase thus appear to be excellent gene combinations for use with CPA in P450/prodrug activation-based cancer gene therapy.
|
9766669 |
1998 |
|
Cardiovascular Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
These alterations induced by Type II diabetes in the endogenous pathway (CYP450) of arachidonic acid metabolism may increase the risk for cardiovascular disease by disrupting the fine equilibrium between cardioprotective (CYP2J/CYP2C-generated) and cardiotoxic (CYP4A/CYP4F-generated) metabolites of arachidonic acid.
|
29023376 |
2017 |
|
Drug abuse
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The described drug abuse cases suggest that an association between the presence of CYP2C and VKORC1 allelic variants and cocaine-induced interstitial lung damage is highly likely.
|
21766908 |
2011 |
|
Disorder of eye
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We hypothesized that inhibition of CYP2C activity will add to the protective effects of ω-3 LCPUFA on neovascular eye diseases.
|
27417579 |
2016 |
|
Caffeine related disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The five probe substrates were caffeine (2 mg/kg), bupropion (30 mg/kg), omeprazole (4 mg/kg), dextromethorphan (40 mg/kg), and midazolam (2 mg/kg) for CYP1A, CYP2B, CYP2C, CYP2D, and CYP3A, respectively.
|
29550976 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
CYP2B6 plus P450 reductase and CYP2C18-Met plus P450 reductase thus appear to be excellent gene combinations for use with CPA in P450/prodrug activation-based cancer gene therapy.
|
9766669 |
1998 |